デフォルト表紙
市場調査レポート
商品コード
1356794

抗結核治療薬市場レポート:2030年までの動向、予測、競合分析

Anti-Tuberculosis Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

抗結核治療薬市場レポート:2030年までの動向、予測、競合分析
出版日: 2023年09月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

抗結核治療薬の動向と予測

世界の抗結核治療薬市場は、2024年から2030年までのCAGRが7.1%で、2030年までに推定21億米ドルに達すると予想されます。この市場の主な促進要因は、結核有病率の増加、結核啓発に対する政府組織のイニシアチブの高まり、新興諸国におけるMDRおよびXDR症例の急増です。世界の抗結核治療薬市場の将来性は、病院、専門クリニック、在宅医療市場における機会によって有望視されています。

抗結核治療薬市場の洞察

Lucintelの予測では、結核患者の増加と結核治療へのイソニアジドの採用増加により、イソニアジドが予測期間中に最も高い成長を遂げる見込みです。

この市場において、病院が最大のセグメントであり続けると思われます。

アジア太平洋は、政府イニシアチブの拡大、ジェネリックメーカーの増加、同地域におけるヘルスケアインフラの継続的な開発により、予測期間中に最も高い成長が見込まれます。

本レポートでは、以下の11の主要な質問に回答している:

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か?
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は?
  • Q.3.今後成長が加速すると思われる地域とその理由は?
  • Q.4.市場力学に影響を与える主な要因は何か?市場における主な課題とビジネスリスクは?
  • Q.5.この市場におけるビジネスリスクと競合の脅威は?
  • Q.6.この市場における新たな動向とその理由は?
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか?
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は?
  • Q.9.この市場における主要企業は?主要企業は事業成長のためにどのような戦略的取り組みを進めているのか?
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか?
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか?

目次

第1章 エグゼクティブサマリー

第2章 世界の抗結核薬市場:市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向(2018~2023年)と予測(2024~2030年)
  • 世界の抗結核薬市場動向(2018-2023)と予測(2024-2030)
  • タイプ別の世界の抗結核治療薬市場
    • 活動性結核
    • 潜在性結核
    • その他
  • 薬物クラス別の世界の抗結核薬市場
    • イソニアジド
    • リファンピン
    • エサンブトール
    • ピラジナミド
    • フルオロキノロン類
    • ベダキリン
    • アミノグリコシド
    • チオアミド
    • 環状ペプチド
  • 最終用途別の世界の抗結核治療薬市場
    • 病院
    • 専門クリニック
    • ホームケア
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の抗結核薬市場
  • 北米の抗結核薬市場
  • 欧州の抗結核薬市場
  • アジア太平洋抗結核治療薬市場
  • その他地域抗結核治療薬市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • 種類別の世界の抗結核治療薬市場の成長機会
    • 医薬品クラス別の世界の抗結核治療薬市場の成長機会
    • 最終用途別の世界の抗結核治療薬市場の成長機会
    • 地域別の世界の抗結核治療薬市場の成長機会
  • 世界の抗結核薬市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の抗結核治療薬市場の能力拡大
    • 世界の抗結核治療薬市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Lupin
  • Macleods
  • Otsuka
  • Johnson & Johnson
  • Sequella
  • Novartis
  • Akorn
  • Fresenius SE
  • Viatris
目次

Anti-Tuberculosis Therapeutics Trends and Forecast

The future of the global anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.

A more than 150-page report is developed to help in your business decisions.

Anti-Tuberculosis Therapeutics by Segment

The study includes a forecast for the global anti-tuberculosis therapeutics by type, drug classes, end use, and region.

Anti-Tuberculosis Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Active TB
  • Latent TB
  • Others

Anti-Tuberculosis Therapeutics Market by Drug Classes [Shipment Analysis by Value from 2018 to 2030]:

  • Isoniazid
  • Rifampin
  • Ethambutol
  • Pyrazinamide
  • Fluoroquinolones
  • Bedaquiline
  • Amynoglycosides
  • Thioamides
  • Cyclic Peptides
  • Others

Anti-Tuberculosis Therapeutics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Anti-Tuberculosis Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Anti-Tuberculosis Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies anti-tuberculosis therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the anti-tuberculosis therapeutics companies profiled in this report include-

  • Lupin
  • Macleods
  • Otsuka
  • Johnson & Johnson
  • Sequella
  • Novartis
  • Akorn
  • Fresenius Se
  • Viatris

Anti-Tuberculosis Therapeutics Market Insights

Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.

Within this market, hospitals will remain the largest segment due to .

APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.

Features of the Global Anti-Tuberculosis Therapeutics Market

Market Size Estimates: Anti-tuberculosis therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Anti-tuberculosis therapeutics market size by type, drug classes, end use, and region. in terms of value ($B).

Regional Analysis: Anti-tuberculosis therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, drug classes, end uses, and region.s for the anti-tuberculosis therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the anti-tuberculosis therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the anti-tuberculosis therapeutics market size?

Answer: The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030.

Q.2. What is the growth forecast for anti-tuberculosis therapeutics market?

Answer: The global anti-tuberculosis therapeutics market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the anti-tuberculosis therapeutics market?

Answer: The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.

Q.4. What are the major segments for anti-tuberculosis therapeutics market?

Answer: The future of the anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key Anti-Tuberculosis Therapeutics Market companies?

Answer: Some of the key anti-tuberculosis therapeutics companies are as follows:

  • Lupin
  • Macleods
  • Otsuka
  • Johnson & Johnson
  • Sequella
  • Novartis
  • Akorn
  • Fresenius SE
  • Viatris

Q.6. Which anti-tuberculosis therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.

Q.7. In anti-tuberculosis therapeutics market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the anti-tuberculosis therapeutics market by type (active TB, latent LB, and others), drug classes (isoniazid, rifampin, ethambutol, pyrazinamide, fluoroquinolones, bedaquiline, amynoglycosides, thioamides, cyclic peptides, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Anti-Tuberculosis Therapeutics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Anti-Tuberculosis Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Anti-Tuberculosis Therapeutics Market by Type
    • 3.3.1: Active TB
    • 3.3.2: Latent TB
    • 3.3.3: Others
  • 3.4: Global Anti-Tuberculosis Therapeutics Market by Drug Classes
    • 3.4.1: Isoniazid
    • 3.4.2: Rifampin
    • 3.4.3: Ethambutol
    • 3.4.4: Pyrazinamide
    • 3.4.5: Fluoroquinolones
    • 3.4.6: Bedaquiline
    • 3.4.7: Amynoglycosides
    • 3.4.8: Thioamides
    • 3.4.9: Cyclic Peptides
  • 3.5: Global Anti-Tuberculosis Therapeutics Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Specialty Clinics
    • 3.5.3: Homecare
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Anti-Tuberculosis Therapeutics Market by Region
  • 4.2: North American Anti-Tuberculosis Therapeutics Market
    • 4.2.2: North American Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Anti-Tuberculosis Therapeutics Market
    • 4.3.1: European Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
    • 4.3.2: European Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Anti-Tuberculosis Therapeutics Market
    • 4.4.1: APAC Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
    • 4.4.2: APAC Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Anti-Tuberculosis Therapeutics Market
    • 4.5.1: ROW Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
    • 4.5.2: ROW Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Type
    • 6.1.2: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Drug Classes
    • 6.1.3: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by End Use
    • 6.1.4: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Region
  • 6.2: Emerging Trends in the Global Anti-Tuberculosis Therapeutics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Anti-Tuberculosis Therapeutics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Anti-Tuberculosis Therapeutics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Lupin
  • 7.2: Macleods
  • 7.3: Otsuka
  • 7.4: Johnson & Johnson
  • 7.5: Sequella
  • 7.6: Novartis
  • 7.7: Akorn
  • 7.8: Fresenius SE
  • 7.9: Viatris